How Can Abemaciclib Play a Role in MBC?

Dear Dr. Renukaprasad A R, If cancer does not take a day off, then why should a CDK 4/6 inhibitor? Rapid cell proliferation and drug resistance make metastatic breast cancer (MBC) difficult to treat. Abemaciclib, the cyclin-dependent kinase 4 and 6 (CDK 4/6) inhibitor, works by blocking the action of an abnormal CDK 4/6 protein that causes cancer cell proliferation. As a result, the drug helps slow down or stop cancer cells from proliferating. Attend this exclusive webinar on the 21st of July 2022 at 07:00 PM IST with the renowned oncology experts, Dr. Shaheenah Dawood, Dr. Sudeep Gupta, Dr. Ashish Singh, Dr. B. K. Smruti, Dr. Shruti Kate, and Dr. Shirish Alurkar, to learn more about the clinical role of abemaciclib in treating MBC patients with poor prognosis. Session details : Abemaciclib - Different by design Responses in MBC patients Clinical case presentation on the role of abemaciclib by Dr. Shaheenah Dawood, Dr. Shruti Kate, Dr. Shirish Alurkar, and Dr. B. K. Smruti Q&A with the experts - Tailoring treatment in HR+ HER2- MBC patients based on poor prognostic factors We look forward to your enthusiastic participation! Join the Session   India's Largest Online Community of Verified Doctors Pune - 411045, India info@docplexus.co.in�� |� +91 98500 36954 You are receiving this communication because you are registered member of Docplexus. Unsubscribe from this mailing list. *|LIST:DESCRIPTION|* *|LIST:ADDRESS|* *|REWARDS_TEXT|*